Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZTC -- Ignore unavailable to you. Want to Upgrade?

To: kinkblot who wrote (618)	9/22/1999 9:10:00 AM
From: kinkblot	Read Replies (1) \| Respond to of 752

The golden goats story on page D1 of today's Globe: boston.com and a nice picture of the goats from the main Business page: boston.com [links will expire] Ballpark figures on production costs from Dr. Sandra Lehrman, president of Genzyme Transgenics: "If you look at the capital needed to make 100 kilograms per year of a pharmaceutical the traditional way with bricks, mortar, bio-reactors, and stainless steel, initial production will cost between $20 million and $70 million. With transgenic goats, the costs are between $2 million and $5 million to produce the same amount with probably 35 goats, each producing 5 to 10 grams of the protein per liter of milk. It's a great business."

To: kinkblot who wrote (618)	9/23/1999 11:03:00 PM
From: kinkblot	Read Replies (1) \| Respond to of 752

A Perspective on the study by O'Reilly et al., "How Serpins Are Shaping Up" by R.W. Carrell, in Science 17 Sep 1999, p 1861. Interesting concluding paragraph: ...Importantly, as the authors ask, will these modified forms have clinical efficacy? The good news is that there should be no hindrance to human therapeutic trials for infusion of L-antithrombin, as such material has been used unwittingly in transfusion medicine for more than 10 years. At least one manufacturer of antithrombin concentrates has, in a final pasteurization step, been converting up to 40% of the antithrombin into latent and other L-forms. A controlled trial of transfusions of multigram quantities of these concentrates showed no adverse effects. Frustratingly, patients with malignancies were excluded from the trial! The latent and locked L-forms and the cleaved form are the conformations referred to by O'Reilly in his paper as antiangiogenic AntiThrombin based on their observed activity. He produced the latent form for his experiments by heat treating antithrombin with a citrate.